statex 40 mg filmsko obložene tablete
teva pharma b.v. - simvastatin - filmsko obložena tableta - simvastatin 40 mg / 1 tableta - simvastatin
statex 5 mg filmsko obložene tablete
teva pharma b.v. - simvastatin - filmsko obložena tableta - simvastatin 5 mg / 1 tableta - simvastatin
statex 80 mg filmsko obložene tablete
teva pharma b.v. - simvastatin - filmsko obložena tableta - simvastatin 80 mg / 1 tableta - simvastatin
blincyto
amgen europe b.v. - blinatumomab - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
bosulif
pfizer europe ma eeig - bosutinib (kot monohidrat) - leukemija, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif je indiciran za zdravljenje odraslih bolnikov z:novo diagnozo kronična faza (cp) philadelphia kromosom-pozitivno kronične myelogenous levkemijo (ph+ cml). cp, pospešeni fazi (ap), in pišu faza (bp) ph+ cml predhodno zdravljenih z eno ali več tirozin kinaza serotonina(s) [tki(s)] in za koga imatinib, nilotinib in dasatinib ki se ne štejejo za ustrezne možnosti zdravljenja.
kineret
swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - imunosupresivi - revmatoidni artritis (ra)kineret je navedeno pri odraslih za zdravljenje znakov in simptomov ra v kombinaciji z metotreksatom, z nezadosten odziv na sam metotreksat. covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml. periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret je treba v kombinaciji z colchicine, če je primerno. Še vedno je diseasekineret je navedeno pri odraslih, mladostnikov, otrok in dojenčkov, starih od 8 mesecev in več s telesno maso 10 kg ali več, za zdravljenje še vedno je bolezen, vključno s sistemsko mladoletnike idiopatsko artritis (sjia) in odrasle-nastop še vedno je bolezen (aosd), z aktivnim sistemske značilnosti zmerno do visoko aktivnosti bolezni, ali pri bolnikih s nadaljevanje aktivnosti bolezni po zdravljenju z nesteroidna protivnetna zdravila (nesteroidnih protivnetnih zdravil) ali glucocorticoids. kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).
rydapt
novartis europharm ltd - midostaurin - leukemia, myeloid, acute; mastocytosis - antineoplastična sredstva - rydapt je navedeno:v kombinaciji s standardno daunorubicin in cytarabine indukcije in visok odmerek cytarabine konsolidacije kemoterapijo, in za bolnike v popolni odgovor sledi rydapt en agent za vzdrževanje terapija, pri odraslih bolnikih, ki so na novo zboleli za akutno mieloično levkemijo (aml), ki so flt3 mutacije pozitivna (glej poglavje 4. 2);kot monotherapy za zdravljenje odraslih bolnikov z agresivno sistemske mastocytosis (asm), sistemsko mastocytosis s povezanimi hematoloških neoplasm (sm ahn), ali jambor celice levkemijo (mcl).
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
intralipid 200 mg/ml emulzija za infundiranje
medias international d.o.o. - sojino olje, prečiščeno - emulzija za infundiranje - sojino olje, prečiščeno 200 mg / 1 ml - maščobne emulzije
intralipid 200 mg/ml emulzija za infundiranje
medias international d.o.o. - sojino olje, prečiščeno - emulzija za infundiranje - sojino olje, prečiščeno 200 mg / 1 ml - maščobne emulzije